Santhera Pharmaceuticals Holding AG : Santhera Explores Strategic Options; Updates Financial Calendar Santhera Pharmaceuticals Holding AG / Santhera Explores Strategic Options; Updates Financial Calendar . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. Liestal, Switzerland, February28, 2013 - Santhera Pharmaceuticals (SIX:SANN) announced today that following the voluntary withdrawal of Catena^® from the Canadian market and the earlier negative decision of the Committee for Medicinal Products for Human Use (CHMP) on the Market Authorization Application for Raxone^® in Leber's Hereditary Optic Neuropathy (LHON), the Board has decided to consider strategic options including product licensing for Raxone^® in LHON and the possibility of a merger or acquisition. Santhera has already received expressions of interest from third parties and has retained Piper Jaffray Limitedto assist the Company in this process. The publication of the financial results for 2012 will be postponed and, together with the financial outlook for 2013, will now be provided within the timelines required by the SIX regulations. Accordingly, the Company will therefore postpone the Annual Shareholders' Meeting previously planned for April22, 2013. Shareholders should note that whilst the Board believes that it is in the best interest of shareholders to explore these options and take the steps described, there can be no guarantee that any transaction can be consummated. * * * About Santhera Santhera Pharmaceuticals (SIX:SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan neuromuscular and mitochondrial diseases, areas of high unmet medical need with no current therapies. For further information, please visit www.santhera.com. For further information, contact Thomas Meier, Chief Executive Officer Phone: +41 61 906 89 64 firstname.lastname@example.org Disclaimer / Forward-looking statements This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements. News release ------------------------------------------------------------------------------ This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Santhera Pharmaceuticals Holding AG via Thomson Reuters ONE HUG#1681770 --- End of Message --- Santhera Pharmaceuticals Holding AG Hammerstrasse 49 Liestal Switzerland ISIN: CH0027148649;
Santhera Pharmaceuticals Holding AG : Santhera Explores Strategic Options; Updates Financial Calendar
Press spacebar to pause and continue. Press esc to stop.